https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-782010-08-24 00:00:002019-02-15 08:49:24Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-192010-07-27 00:00:002010-07-27 00:00:00Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / J. Virol. 2010 Jan;84(1):639-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / J. Virol. 2010 Jan;84(1):639-462010-01-01 00:00:002010-01-01 00:00:00The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Melanoma Res. 2009 Oct;19(5):309-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Melanoma Res. 2009 Oct;19(5):309-152009-10-01 00:00:002019-02-15 08:49:26Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-29 / Clin. Cancer Res. 2009 Oct;15(19):6267-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-29 / Clin. Cancer Res. 2009 Oct;15(19):6267-762009-09-29 00:00:002019-02-15 08:36:11Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-15 / Prostate 2009 Jun;69(9):938-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-15 / Prostate 2009 Jun;69(9):938-482009-06-15 00:00:002019-02-15 08:53:14Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-642009-05-07 00:00:002019-02-15 08:49:27Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-05 / Clin. Cancer Res. 2009 May;15(10):3366-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-05 / Clin. Cancer Res. 2009 May;15(10):3366-752009-05-05 00:00:002019-02-15 08:49:28Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Hum. Immunol. 2009 May;70(5):331-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Hum. Immunol. 2009 May;70(5):331-92009-05-01 00:00:002019-02-15 09:19:12Melanoma vaccines: The problems of local immunosuppression
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-402009-03-24 00:00:002019-02-15 08:49:29Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
